Publication | Closed Access

A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy

OncologyCancer ManagementPharmacologyPhase Ii StudyBronchial NeoplasmPharmacotherapyCancer TreatmentFirst-line ChemotherapyMedicineCancer ChemotherapyLung Cancer